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Free radicalsThe only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modifica-
tion. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the sily-
bin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a
multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented
NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified pri-
mary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma
levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and
quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD
score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers.
We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely with-
drawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally
well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs)
were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Pa-
tients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and
liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in
the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to system-
atically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated withnotransferase; ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; HOMA, homeostatic model as-
se; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis; P, placebo; PP,
rowth factor; TIMP, tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor; γGT, γ-glutamyltranspeptidase.
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These findings warrant further investigation.
© 2012 Elsevier Inc. All rights reserved.Nonalcoholic fatty liver disease (NAFLD) is an important emerging
liver damage epidemic. When characterized by only steatosis, NAFLD
is associated with increased cardiovascular risk and worsens the
course of hepatitis C; when represented by nonalcoholic steatohepa-
titis (NASH), NAFLD can evolve into liver fibrosis and cirrhosis [1,2].
Currently there is no effective therapy for NAFLD, except for lifestyle
modification [3]. Both dysregulated glucose metabolism and oxida-
tive stress in hepatocytes are key pathogenic factors in the onset of
steatosis and progression of NASH, its inflammatory and potentially
evolutive form. Studies have shown that insulin-sensitizing agents
and antioxidants may improve clinical and histologic features of
NAFLD, although data remain inconclusive [4,5].
Silybin is a potent antioxidant representing about 50–70% of the
silymarin extract of Silybum marianum (milk thistle). Silybin mod-
ulates inflammation and fibrogenesis and interferes with intrahe-
patic glycolysis and gluconeogenesis [6,7]. Silybin treatment
attenuated liver damage and diabetes in animal models of NASH
and type 1 diabetes mellitus [8–11] and showed benefits in pa-
tients with poorly controlled type 2 diabetes with or without alco-
holic liver cirrhosis [12,13].
As with other flavolignans, limitations of silybin use include low
water solubility, low bioavailability, and poor intestinal absorption
[14]. Derivatives of silybin with improved solubility may surmount
these pharmacologic limitations [15,16]. The silybin phytosome com-
plex (silybin plus phosphatidylcholine) has been coformulated with
vitamin E (Realsil (RA); Istituto Biochimico Italiano, Lorenzini S.p.a.,
Italy). Pharmacokinetic analyses indicated that silybin phytosome
bioavailability is much higher than silymarin bioavailability [17,18].
Given the potentially beneficial effects of silybin on liver function,
and the need for effective therapies for liver steatosis, we carried out
a placebo-controlled, double-blind, phase III, randomized clinical trial
to assess RA in NAFLD patients.
Experimental procedures
Trial design
The trial was conducted at 11 Italian and 2 Romanian centers. Pro-
tocol and patient consent forms were designed by the coordinating
center and reviewed by all participating centers. The protocol con-
formed to ethical guidelines of the 1975 Declaration of Helsinki and
was approved by the Institutional Review Board at each participating
center. All patients gave informed written consent. The trial was reg-
istered with the European Clinical Trials Database (EudraCT, Ref.
2005-000860-24). No significant changes were made to the protocol
or prespecified outcomes after trial commencement.
Inclusion criteria were histologically documented liver steatosis or
steatohepatitis diagnosed within 12 months, age 18–65, persistent in-
crease in ≥1 plasma aminotransferase (aspartate aminotransferase
(AST) and/or alanine aminotransferase (ALT)) and/or γ-
glutamyltranspeptidase (γGT) within 6 months, and negative preg-
nancy test (females). Hepatitis C virus (HCV)-positive patients (con-
firmed by HCV RNA assay)+NAFLD with prior HCV treatment
failure could enroll. Even if both pathogenesis and treatment of
HCV-related chronic hepatitis were very different from NAFLD/
NASH, in this study we aimed to verify the effect of RA on the meta-
bolic component of fatty liver also in HCV-positive patients.
Exclusion criteria were liver cirrhosis, presence of other major dis-
eases including type 1 diabetes, hepatitis B or D infection, genotype 3
HCV infection, any treatment for liver disease or HCV infection within6 months, participation in other trials, hypersensitivity to treatment,
daily ethanol consumption ≥20 g, and substance abuse. Drinking
habits were assessed by questionnaires on lifetime drinking history
and self-administered AUDIT C test [19,20]. Patients with normal
values of one liver enzyme at baseline (T0) were not excluded.
Patients were allocated (1:1) to receive active treatment (RA; ac-
tive components: silybin 94 mg, phosphatidylcholine 194 mg, vita-
min E acetate 50% (α-tocopherol 30 mg) 89.28 mg) or placebo (P;
extrawhite saccharine replacing active components) orally twice
daily for 12 consecutive months, on a consecutive basis within each
site according to a centrally randomized list generated by block allo-
cation. The block allocation sequence was based on numbers random-
ly generated by a computer program and randomization was not
stratified. Investigators recorded patients’ randomization numbers
on the case report form. Patients and investigators were blinded to
treatment until trial completion; treatment assignment code was
sealed in the randomization envelopes.
Other treatments were disallowed. Patients received recommen-
dations for lifestyle modification and an individually designed diet,
plus dietary recommendations including reduction of simple carbo-
hydrates (glucose, sucrose, fructose), fatty dressings (butter, mayon-
naise), fatty cheeses, and sausages and increases in vegetable proteins
and fiber.
Patients with b70% treatment compliance or who missed a visit
were withdrawn.
Clinical and laboratory assessments
Clinical history, physical examination, and liver biopsy results
were recorded at baseline; histology was defined by NAFLD activity
score (NAS) [21]. NAS uses a standardized grading system for steato-
sis (0 to 3), lobular inflammation (0 to 3), and hepatocellular bal-
looning (0 to 2), higher scores indicating increased severity.
Monthly check-ups assessed compliance, adverse events (AEs), and
drug delivery; patients had to record their drug consumption daily.
AST, ALT, and γGT plasma levels were determined at baseline and
every 3 months. The following assessments were completed at base-
line, 6 months (T6), and 12 months (T12): body mass index (BMI;
overweight, BMI ≥25 and b30 kg/m2; obese, BMI ≥30 kg/m2); ab-
dominal circumference and waist-to-hip ratio; abdominal ultraso-
nography (severity graded on semiquantitative scale: 0, absent; 1,
mild; 2, moderate; and 3, severe) [22]; quality of life (QoL; 36-item
short-form health survey (SF-36)) [23]; routine biochemistry tests
(blood urea nitrogen, creatinine, bilirubin, total protein, alkaline
phosphatase, uric acid, blood cell count, and prothrombin activity);
HCV RNA levels (HCV-positive patients); plasma levels of glucose,
triglycerides, cholesterol, ferritin, and insulin; and homeostatic
model assessment (HOMA) [24]. Cytokines (tumor necrosis factor
α (TNF-α), interleukin 10 (IL-10), transforming growth factor β
(TGF-β)) and liver fibrosis markers (hyaluronic acid, matrix metallo-
proteinase 2 (MMP-2), procollagens I and III, tissue inhibitor of
metalloproteinases 1 and 2 (TIMP-1 and -2)) were assessed at base-
line and at T12 [25,26]. A second liver biopsy was performed at T12 if
allowed by the Institutional Review Board and the patient had re-
signed the informed consent form.
Fasting blood samples were collected and plasma for cytokine
level assessment was stored at −80 °C. Cytokines and markers of
liver fibrosis were assessed by the coordinating center using
enzyme-linked immunosorbent assay kits (IL-10, TNF-α, MMP-2,
TGF-β, R&D Systems, Minneapolis, MN, USA; hyaluronic acid, Echelon
1660 C. Loguercio et al. / Free Radical Biology & Medicine 52 (2012) 1658–1665Biosciences, Salt Lake City, UT, USA; procollagen I, Takara Bio, Otsu,
Shiga, Japan; procollagen III, USCN Life Science, Wuhan, China;
TIMP-1, Invitrogen, Carlsbad, CA, USA; TIMP-2, Chemicon Internation-
al, Millipore, Billerica, MA, USA).
Although trial eligibility was determined by each site's pathologist
using locally prepared tissue sections, the final analysis used centrally
prepared sections (stained with hematoxylin and eosin, Chromotrope
aniline blue trichrome, Sweet's reticulin, Sirius red, periodic acid–
Schiff, periodic acid–Schiff diastase, and Pearl's and immunostained
for ubiquitin) reviewed by two pathologists (blinded to clinical
data/treatment) with liver histopathology experience. Steatohepatitis
was assessed using a protocol incorporating histologic features for
NASH grading/staging [21,27] and using NAS. Liver damage (HCV-
infected patients) was graded by Ishak score [28], with evaluation
also of perisinusoidal/pericellular fibrosis when present.
Statistical analyses
Sample size assumptions incorporated preliminary data [29,30],
showing 23–25% efficacy with RA versus 6–10% with P. Additional as-
sumptions included improvement in clinical condition, normalization
of biochemical index, planned accrual period of 1 year, and minimum
6-month treatment period. Estimated sample size (two-tailed α error
of 5%, β potency of 90%) was 90 patients per group plus an estimated
lost-to-follow up rate of 10% (200 patients in total).
Prespecified primary outcomes were clinical conditions; AST, ALT,
and/or γGT plasma level normalization; ultrasonographic liver stea-
tosis improvement; HOMA; and QoL (SF-36). Secondary outcomes
were liver histologic score improvement of hepatocellular steatosis
points and/or NAFLD activity score decrease points, without fibrosis
worsening, and plasma level changes in cytokines, ferritin, and liver
fibrosis markers.
Based on residual treatment sachets presented at check-ups, pa-
tient compliance was calculated as (1−(Va−Vo)/Va)×100 (Va is the
number of sachets a patient received; Vo is the number of sachets
returned).
The efficacy evaluation of the study made with the intention to
treat analysis and with the per protocol analysis was aimed at esti-
mating the frequency of success at the final visit (for the subjects con-
sidered responders). An interim analysis was done at the 6th month.
According to protocol, all data were described with contingency ta-
bles and with classical descriptive statistics (minimum, maximum,
media, standard deviation, median, etc). The entire hypothesis was
tested with a double-tailed test.
Primary and secondary outcomes are reported separately for HCV-
negative and -positive patients. All analyses are per protocol (PP), ex-
cept liver histology (T0 versus T12) analyzed in all randomized pa-
tients who received treatment ≥6 months with compliance ≥70%.
PP analyses excluded patients not meeting inclusion/exclusion cri-
teria, consuming disallowed medication, with compliance b70%, or
not attending the final visit. Data missing after T12 were imputed by
last observed carried forward. No exploratory or post hoc analyses
were conducted.
The statistical tests used to evaluate the efficacy and tolerability of
treatments were done with a significance level of 5% (pb0.05) to en-
sure an error of 5%.
The evaluation of the study was planned with intention-to-treat
analysis, considering all the primary variables and all the secondary
variables. Also a PP analysis was planned, considering the primary
variables and the analysis of the histological scores.
Primary end-point analysis
The primary efficacy variable was to be analyzed using double-
entry contingent tables and χ2 test. The primary variables between
and into the groups at any time (0, 3, 6, 9, and 12 months) were to
be evaluated using the analysis of variance, whereas thenonparametric data were evaluated by means of McNemar or
Cochran test and χ2 test.
An eventual analysis could be made to quantify the association
between two or more variables with correlation test or multivari-
ate analysis.
Secondary end-point analysis
The evaluation of secondary variables was planned for dichotomic
variables with nonparametric tests, whereas for continuous variables,
parametric or nonparametric tests were used, according to sample
distribution. The statistical evaluation of data was performed for any
time of the study (0, 3, 6, 9, and 12 months).
Demographic data were analyzed by descriptive statistics includ-
ing mean, standard deviation, standard error of the mean (SE) and
95% confidence interval. Sample homogeneity for descriptive vari-
ables was verified by χ2 test or Fisher exact test; continuous variables
were verified by Student t test (independent data). Normal distribu-
tion of data was assessed by Kolmogorov–Smirnov test. For continu-
ous variables, differences between or within groups was analyzed
by two-tailed analysis of variance. Tukey–Friedman and Wilcoxon
tests were used for multiple comparisons. The Mann–Whitney test
was used to analyze data between groups if the data were not nor-
mally distributed. Discrete/codified variables and dichotomic vari-
ables were analyzed over time by Cochran or McNemar test and
between groups by χ2 test. The Cohen κ test was performed to verify
concordance of the clinical diagnosis index. Spearman's rank correla-
tion index (r) was used to investigate the association between clinical
and biochemical data and liver histology.
Statistical analyses were performed using SPSS (version 17; IBM
Corp., Somers, NY, USA) and/or Statistica (version 8.0; StatSoft,
Tulsa, OK, USA) software. nQuery Advisor (version 4.0; Statistical So-
lutions Ltd, Cork, Ireland) was used for sample size calculation.
Results
The trial took place from 13 June 2005 to 10 October 2008 and en-
rolled 180 patients with histologically proven NAFLD; 36 were HCV
positive. Overall, 91 patients received RA and 88 received P. Forty-
one patients were prematurely withdrawn (22 and 19 from the RA
and P groups, respectively), with 138 patients available for PP analy-
sis (69 in each group). Reasons for discontinuation were physician's
decision (n=5), patient's decision (n=21), AEs (n=10), or other
(n=5). AEs were generally transient and included diarrhea, dysgeu-
sia, and abdominal pain. No serious AEs related to the study drug
were recorded.
Baseline characteristics were generally well balanced between
groups. One hundred eight patients entered the study with NAFLD
(RA group, M/F 47/8, mean age 40.8±10.3, BMI 29.9±4.6, waist/
hip ratio 0.94±0.09, abdominal circumference 105±10 cm; P
group, M/F 43/10, mean age 44.2±9.5, BMI 29.3±4.4, waist/hip
ratio 0.95±0.09, abdominal circumference 102±12 cm) and 30 pa-
tients with NAFLD and HCV chronic infection (RA group, M/F 5/9,
mean age 46.9±10.2, BMI 27.6±3.6, waist/hip ratio 0.89±0.08,
abdominal circumference 103±12 cm; P group, M/F 7/9, mean age
50.9±9.5, BMI 27.8±3.4, waist/hip ratio 0.91±0.06, abdominal
circumference 102±15 cm). The main biochemical findings are
reported in Table 1. Basal hypercholesterolemia was found in about
50% of subjects in all groups, hypertriglyceridemia in a range from
20 to 49%, and hyperferritinemia in 20–30% of cases, without signifi-
cant differences in all groups. Under basal condition, both cytokines
and plasma markers of liver fibrosis did not differ from normal values
or among groups. The score for ultrasonographic liver steatosis was 1
or 2 in about 40% of cases each, whereas it was 3 in only 20% of
patients. No differences for this parameter were registered among
the groups.
Table 1
Baseline main biochemical findings of patients evaluated by PP analysis.
NAFLD (n=108) NAFLD and HCV infection
(n=30)
RA group P group p
(RA vs P)
RA group P group p
(RA vs P)
HOMA 4.9±3.6 4.6±3.0 n.s. 6.3±4.1 4.8±3.3 n.s.
AST (IU/L) 52±40 56±20 n.s. 75±30 83±70 n.s.
ALT (IU/L) 49±35 52±30 n.s. 84±40 87±32 n.s.
γGT (IU/L) 73±30 75±31 n.s. 74±40 79±23 n.s.
Cholesterol
(mg/dl)
200±50 190±35 n.s. 197±40 189±30 n.s.
Triglycerides
(mg/dl)
153±65 160±58 n.s. 154±45 167±55 n.s.
Ferritin
(ng/ml)
220±100 234±95 n.s. 240±45 237±70 n.s.
Means±standard deviation. Total n=138. PP, per protocol; NAFLD, nonalcoholic fatty
liver disease; RA, Realsil; P, placebo; HOMA, homeostatic model assessment; AST, aspar-
tate aminotransferase; ALT, alanine aminotransferase; γGT, γ-glutamyltranspeptidase;
IU, international units; n.s., not significant.
Fig. 1. Proportions of patients whose plasma levels of (a) AST, (b) ALT, and (c) γGT nor-
malized over time. p=0.03 for γGT between RA and P at T12. *pb0.05 vs basal;
**pb0.001 vs basal. ALT, alanine aminotransferase; AST, aspartate aminotransferase;
γGT, γ-glutamyltranspeptidase; P, placebo; RA, Realsil; T12, 12 months; Vis, visit at
month.
Fig. 2. Proportion of patients with normalized γGT plasma values among those with ab-
normal γGT levels at baseline. *pb0.05 vs basal; **pb0.001 vs basal; +pb0.001 for RA
vs P group. γGT, γ-glutamyltranspeptidase; P, placebo; RA, Realsil; Vis, visit at month.
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Liver enzymes
Baseline plasma values of AST, ALT, or γGT were in the normal
range in many patients. Fig. 1 summarizes the liver enzyme changes.
With RA, but not P, the proportion of patients with normalized AST
levels progressively increased (43 and 15% in the RA and P groups, re-
spectively, pb0.001 at T12 in the RA group vs baseline). Similarly, the
proportion of patients with normalized ALT values significantly in-
creased over time in the RA but not in the P group (41% vs 5%, respec-
tively at T12; pb0.05, pb0.001, and pb0.05 vs baseline at T3, T9, and
T12, respectively). No significant differences were observed between
RA and P at T12.
A significant improvement was observed in γGT with RA
(p=0.0002 at T12 vs baseline) but not with P. Accordingly, the pro-
portion of patients with normalization of γGT levels was higher
with RA than with P from T3 onward (45% vs 19%, respectively, at
T3, pb0.05 vs baseline; pb0.001 vs baseline at T6, T9, and T12). For
γGT, a significant difference was also found between groups
(p=0.03 at T12). Of patients with elevated baseline AST, ALT, or
γGT (Fig. 2), significantly more reached normal levels with RA versus
P at T12 (pb0.01 for each enzyme).
Ultrasonographic liver steatosis
The degree of liver steatosis, assessed by ultrasonography, was not
statistically different between RA and P at T12. In patients with mod-
erate or severe steatosis (score 2 or 3), improvements tended to be
greater at T12 among those receiving RA versus P (41 and 29%, respec-
tively; not significant).
BMI
At baseline, 10 patients receiving RA and 10 receiving placebo had
normal BMI. In the RA and P groups, respectively, 33 and 38 patients
were overweight and 26 and 21 patients were obese. Adherence to
individualized diets was poor in all patients; at T12 no significant
changes in mean BMI were observed in any group. Waist–hip ratio
and abdominal circumference were unaffected by treatment. Among
overweight and obese patients (approximately 85%), BMI had nor-
malized at T12 in 15% of RA patients (pb0.01 vs baseline) versus
2.1% of P patients (not significant). No patient's BMI worsened during
the study, and no relationship was found among BMI, liver enzyme,
and HOMA changes.
HOMA
At baseline four patients had diabetes, one of whom was HCV
positive. At T12, blood glucose was 31% lower versus baseline in RA-treated patients, with no notable difference from baseline in the P
group (not significant between groups). At T12, insulinemia was sig-
nificantly lower than at baseline with RA (p=0.02) but not with P
(p=0.72). HOMA was significantly reduced from baseline to T12
with RA (>10%, p=0.09) but not with P. Among patients with a base-
line HOMA >2.7 (43 and 39 patients with RA and P, respectively; ar-
bitrarily selected threshold), HOMA progressively decreased from T6
onward in the RA group (Fig. 3). In the P group, HOMA transiently de-
creased at T6 but returned to baseline levels by T12.
Table 3
Effect of RA or P treatment on liver histology at T12.
RA group P group
T0 T12 p (T0 vs T12) T0 T12 p (T0 vs T12)
Steatosis 0.004 0.32
Low/moderate 40 75 83 83




Absent/low 63 89 100 100
Moderate 37 11 0 0
Ballooning 0.009 0.11
Absent/low 50 90 75 73
Moderate 50 30 25 25
Fibrosis 0.023 0.69
Absent/minimal 20 60 75 66
Moderate 25 5 0 17
Portal–periportal 15 25 17 9
Perisinusoidal 35 5 0 0










RA, Realsil; P, placebo; T0, baseline; T12, 12 months of treatment; NAS, nonalcoholic
fatty liver disease activity score.
Fig. 3. Mean HOMA in patients with HOMA values >2.7 at basal. *pb0.05 vs basal.
HOMA, homeostatic model assessment; Vis, visit at month.
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In patients completing the study, treatment compliance was good.
QoL did not worsen during the study and no significant changes from
baseline were observed.
Secondary outcomes in NAFLD patients
At baseline, 63 patients had only liver steatosis; 45 had NASH
according to established scores [21]. Among HCV-positive patients,
23 (77%) had only steatosis and 7 had NASH. Only 35 patients agreed
to liver biopsy after treatment: 32 with NAFLD (9 of whom had
NASH) and 3 HCV-positive patients (1 with NASH). Results are
given for this subset of double-biopsied patients receiving 12 months’
treatment.
At baseline, there were significant correlations among several clin-
ical, biochemical, and histologic characteristics (Table 2). Histologic
changes over time are summarized in Table 3. The mean severity
score for liver steatosis significantly decreased from baseline to T12
with RA (38%, p=0.004) but not P. Lobular inflammation, ballooning,
and NAS were significantly improved by RA; liver fibrosis was signif-
icantly reduced between baseline and T12 with RA (p=0.023) but not
P. No significant differences were found any of the groups for other
histological characteristics evaluated, such as ubiquitin, Mallory bod-
ies, portal infiltration, and siderosis.
When looking at the NAS comparison, the end results are very
similar numbers (3.47 vs 3.32); however, at the end of the study,
after the randomization and the central revision of the histological
samples, a discrepancy between RA and P groups under basal condi-
tions was found, and the RA group started with a higher NAS with re-
spect to that of the P group.
At baseline, TGF-β levels were significantly inversely correlated
with ballooning (p=0.004) and NAS (p=0.008) and directly corre-
lated with fibrosis (p=0.009). TNF-α levels were significantly corre-
lated with histologic steatosis (pb0.01). Alterations in plasma levels
of cytokines were sporadic and not influenced by treatment.Table 2
Statistical correlation at baseline between clinical and biochemical characteristics and liver
Characteristic (r) AST ALT BMI
Steatosis — 0.29 (0.001) —
Lobular inflammation 0.19 (0.05) — —
Ballooning 0.17 (0.05) — 0.27
NAS 0.43 (0.001) 0.24 (0.02) 0.33
Portal infiltration — — 0.29
Fibrosis 0.22 (0.01) — 0.18
Siderosis — — —
Grading — — —
Ishak score — — —
Results are given for all randomized patients who received treatment for ≥6 months with
Results are shown for characteristics with statistical significance. ITT, intent to treat; AST
HOMA, homeostatic model assessment; TGF-β, transforming growth factor β; NAS, nonalcoPlasma ferritin levels were normal, or close to normal, at baseline
and throughout the study. Additional metabolic parameters, includ-
ing plasma cholesterol and triglycerides, were not significantly influ-
enced by treatment.
Primary and secondary outcomes in HCV-positive patients
Normalization of γGT was observed among HCV-positive patients
and was significantly greater in the RA vs the P group (54% vs 20%, re-
spectively, at T12, p=0.02; pb0.0001 for baseline vs T12 in the RA
group). There were no significant differences in AST or ALT between
RA and P in HCV-positive patients, either at baseline or at T12. At
T12, mean blood glucose was 48% lower than at baseline in HCV-
positive patients treated with RA, with no notable difference for P
(not significant). In patients with a HOMA >2.7 (13 and 12 patients
in RA and P groups, respectively), HOMA significantly decreased be-
tween baseline and T12 with RA (pb0.01) but not P. QoL (social activ-
ity and general health) improved between baseline and T12 in HCV-
positive patients treated with RA (pb0.001).
Hyaluronic acid levels directly correlated with Ishak score
(pb0.01) and TNF-α levels with liver histology grading (pb0.01);
treatment did not influence either. Levels of MMP-2 and TGF-β im-
proved between baseline and T12 in HCV-positive patients in the RA
but not the P group (Fig. 4). No data are available for liver histology,




(0.002) 0.19 (0.03) 0.22 (0.01) −0.25 (0.004)
(0.001) 0.22 (0.03) 0.25 (0.01) −0.27 (0.01)
(0.003) — — —
(0.04) — — −0.23 (0.01)
— — —
— 0.37 (0.05) —
— 0.41 (0.02) —
compliance ≥70%; Spearman's rank correlation index (r) with two-tailed significance.
, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index;
holic fatty liver disease activity score.
Fig. 4. Percentage of decrease at T12 of some plasma markers of liver fibrogenesis
(MMP-2 and TGF-β) in NAFLD and HCV-positive patients treated with RA or P.
*p=0.02 and **p=0.004 vs T0.
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RA-treated NAFLD patients with histologic steatosis improvement
showed a statistically significant ultrasonographic improvement
(pb0.01 vs baseline). In HCV-positive NAFLD patients, the ultrasono-
graphic score improved in 100% of RA patients and 50% of P patients
(p=0.04 between groups). In the latter group, MMP-2 plasma values
were significantly different at T12 versus baseline (pb0.01). In the
NASH subgroup, with or without HCV infection, the proportion of pa-
tients with improved NAS was greater (mean 60% versus 30%) in pa-
tients with improved AST and γGT plasma levels, insulinemia, HOMA,
and ultrasonographic steatosis score (not significant between
groups).
Discussion
This is the first study to systematically assess the effects of silybin
in NAFLD patients, with and without HCV infection. Patients treated
for 12 months with RA, an oral complex containing silybin, phospha-
tidylcholine, and vitamin E, exhibited improvements in levels of
transaminases and γGT, insulin resistance, and several aspects of
liver histology. These improvements were similar to those noted in
patients treated with pioglitazone and vitamin E [4,31]. However, in
our study, body weight did not increase; conversely, we found an un-
expected normalization of BMI in 15% of patients, which warrants fur-
ther investigation.
Currently, no pharmacologic agents are approved for NAFLD or
NASH treatment. Long-term treatment with insulin-sensitizing
agents is debated [5], and chronic use of high-dose vitamin E may
have negative effects [32]. Although the use of herbal products is in-
creasing worldwide, their effects may not be exclusively beneficial
[33]. Preliminary in vitro and in vivo studies of silybin showed an ac-
ceptable safety profile at doses exceeding 10 g/day [29,30,34,35]. This
is important because NAFLD patients are generally younger than
those with other hepatic conditions [36] and may require long-term
treatment. Therefore, to confirm the preliminary positive data, we
designed the present trial to investigate the use of silybin in a typical
population of NAFLD patients.
Interestingly, among patients with chronic HCV infection, 12-
month treatment with RA improved γGT plasma levels, insulin resis-
tance, plasma MMP-2 and TGF-β levels (markers of fibrogenesis), and
QoL. γGT is predictive of liver fibrosis and a marker of the metabolic
syndrome; fibrogenesis, strongly affected by oxidative stress, is the
predominant process of fibrosis; and elevated HOMA is a predictor
of poor PEG-interferon/ribavirin treatment response and hepatocellu-
lar carcinoma in HCV-positive patients [37–41].Our QoL findings echo recent observations by Seeff et al. [42], who
reported benefits of silybin in patients with chronic HCV infection.
Recently, attention has focused on silybin's effects on HCV replication
[43–46]. In this study we found no notable changes in HCV RNA in pa-
tients treated with the stated dose of silybin (data not shown). Unfor-
tunately we could not document possible effects of RA on liver
histology in HCV-infected patients.
Silybin and silymarin have been employed as “hepatoprotectants”
since the Greco-Roman era. In the United States and Europe approxi-
mately 65% of liver disease patients take herbal preparations, primar-
ily those derived from the milk thistle plant (S. marianum) [47,48].
The absence of conclusive efficacy data may be due to the lack of
large, well-designed trials. Studies have frequently been small, with
a lack of appropriate randomization, insufficient information about
the compound used, and wide variations in treatment duration. Addi-
tionally, in the case of milk thistle derivatives, silymarin, silybin, and
other varying compounds are frequently used synonymously [49,50].
We believe that our findings primarily relate to the antioxidant ac-
tion of silybin. Silybin shows antioxidant activity both in vitro and in
experimental animal models, inhibiting radical formation, binding
some radical species (scavenger activity), interfering with lipid mem-
brane peroxidation and permeability, and increasing the concentra-
tion of scavengers in a dose-dependent manner [51]. In human liver
stellate cells, silybin inhibits extracellular signal-related kinase
(ERK), MAP/ERK kinase (MEK), and Raf phosphorylation; reduces
cell migration; and reduces TGF-β-induced synthesis of procollagen
type I and secretion of MMP-2 [29]. ERK-, MEK-, and mitogen-
activated protein kinase-related pathways are regulated and regulate
Jun N-terminal kinase (JNK) expression, which has a pivotal role in
obesity and insulin resistance [52]. Phosphatidylcholine, another
component of the RA preparation, protects against oxidative stress-
mediated liver damage [53,54]. It is unlikely that the treatment effects
are related to the vitamin E component, which is much lower (60 IU/
day) than doses with documented efficacy [4].
More recently, it has been confirmed, in a model of perfused rat
liver, that the hepatoprotectant actions of silybin are related to de-
creased membrane lipid peroxidation, reduced free radical release,
and restoration of the glutathione levels [55]. In vivo, in rats, silybin
treatment, at doses similar to those used in humans, significantly pro-
tected against high-fat-induced fatty liver by stabilizing mitochondri-
al membrane fluidity, reducing serum content of alanine
aminotransferase, decreasing hepatic malondialdehyde, and increas-
ing superoxide dismutase and glutathione levels. Moreover, silybin
enhanced the gene and protein expression of adiponectin and inhib-
ited those of resistin. These results suggest that mitochondrial mem-
brane stabilization, oxidative stress inhibition, and improved insulin
resistance may be the essential mechanisms for the hepatoprotective
effect of silybin on nonalcoholic fatty liver disease in rats [56].
In mice, silybin administration decreased HOMA-IR and serum
ALT and markedly improved hepatic and myocardial damage. Silibi-
nin reduced isoprostanes, 8-deoxyguanosine, and nitrites/nitrates in
the liver and in the heart of db/db mice fed the methionine–cho-
line-deficient diet, whereas glutathione levels were restored to lean
mouse levels in both tissues. Consistently, liver mitochondrial respi-
ratory chain activity was significantly impaired in untreated mice
and was completely restored in silibinin-treated animals. TNF-α
was increased, whereas IL-6 was decreased in both the liver and the
heart of db/db mice fed a methionine–choline-deficient diet. Silibinin
reversed heart TNF-α and IL-6 expression to control mouse levels. In-
deed, liver JNK phosphorylation was reduced to control levels in trea-
ted animals [57]. In obese diabetic mice, silybin administration
markedly decreased plasma levels of asymmetric dimethylarginine,
an endogenous inhibitor of nitric oxide synthase that, as known,
plays a pivotal role in endothelial dysfunction [58]. Finally, the anti-
viral action of silybin against HCV replication is also related to its an-
tioxidant properties. In fact, silybin reduces the levels of some free
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manner it interferes with the regulation of some proteins of the
HCV core (for example, downregulation of HMOX-1 mRNA and upre-
gulation of Nrf2 protein) necessary for HCV replication [59].
Although this trial was designed according to good clinical prac-
tice, several sources of bias are possible in this complex study
designed 6 years ago. Its multicenter nature allowed the inclusion of
more patients, but, despite standardized inclusion criteria, could
have increased interpatient variability. Many patients did not agree
to liver biopsy before/after treatment, which may relate to a lack of
perceived disease among these predominantly asymptomatic pa-
tients. Researchers and patients may have doubted the benefits of a
“dietary supplement,” which could explain the challenges in recruit-
ing patients and centers and the relatively high proportion of drop-
outs. We acknowledge that numerous endpoints were used and that
conclusive therapeutic effects were not always demonstrated. The
latter may relate to sample size; additional data obtained after this
trial began suggested that the sample size assumptions were incor-
rect [29,30].
In conclusion, we show that NAFLD patients treated for 12 months
with RA exhibited improvements in transaminase levels, γGT levels,
insulin resistance, and liver histology, without increases in body
weight. These findings warrant further investigation, particularly for
liver histology. However, this study provides valuable information
that will facilitate the investigation of new therapeutic strategies for
NAFLD patients with or without HCV infection.
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